Pharmacoeconomic Burden of Undertreating Hypertension

Author： Luca Degli Esposti Giorgia Valpiani

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.22, Iss.14, 2004-01, pp. : 907-928

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Global burden of hypertension must be controlled

Inpharma, Vol. 1, Iss. 1471, 2005-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Bimatoprost: A Pharmacoeconomic Review of its Use in Open-Angle Glaucoma and Ocular Hypertension

By Plosker Greg L. Keam Susan J.

PharmacoEconomics, Vol. 24, Iss. 3, 2006-01 ,pp. : 297-314

Adis International

Access to resources Recommend Favorite

Candesartan Cilexetil: A Pharmacoeconomic Review of its Use in Chronic Heart Failure and Hypertension

By Plosker Greg L. Keam Susan J.

PharmacoEconomics, Vol. 24, Iss. 12, 2006-01 ,pp. : 1249-1272

Adis International

Access to resources Recommend Favorite

CV events account for large cost burden in hypertension

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 408-409, 2003-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

The Economic Burden of Glaucoma and Ocular Hypertension: Implications for Patient Management: A Review

By Rouland Jean-François

Drugs & Aging, Vol. 22, Iss. 4, 2005-01 ,pp. : 315-321

Adis International

Access to resources Recommend Favorite